Asundexian
Asundexian has been studied in 2 papers since 2026: 1 trial in people, 1 review; 2 in the past year. The newest paper, Nov 2, 2026: “Efficacy and Safety of Asundexian in Cardiovascular Diseases, Systemic Review and Meta-Analysis”.
2 papers study it4 findingsUpdated
1 new paper in 30 daysSee all 2 papers on asundexian
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country; 2 trials, none about aging.
None of its findings points the other way.
- 1 lab in 1 country
- 2 trials, none about aging
- 2 of 2 trials sponsored by its developers
- Human trial1
What did studies of asundexian find?
2Studies of asundexian measured 2 outcomes; the most studied are major bleeding (1 study) and mortality (1).
Major bleeding
no changein humans1RR 0.79
1 study
Major bleeding
no changein humans1RR 0.79
Asundexian showed no clear effect on major bleeding in humans (cardiovascular disease) (RR 0.79, 95% CI 0.30–2.09).
“asundexian demonstrated a safety profile comparable to control without significant effects on mortality or major bleeding.”
Reviewcardiovascular disease
Efficacy and Safety of Asundexian in Cardiovascular Diseases, Systemic Review and Meta-Analysis
AHA Scientific Sessions 2026 abstract
Mortality
no changein humans1RR 0.98
1 study
Mortality
no changein humans1RR 0.98
Asundexian showed no clear effect on mortality in humans (cardiovascular disease) (RR 0.98, 95% CI 0.85–1.14).
“Asundexian did not significantly affect all-cause mortality compared with control (RR 0.98, 95% CI 0.85–1.14)”
Reviewcardiovascular diseasen = 31,301
Efficacy and Safety of Asundexian in Cardiovascular Diseases, Systemic Review and Meta-Analysis
AHA Scientific Sessions 2026 abstract
What is asundexian linked with?
2Studies link asundexian with 2 measures, most often stroke or systemic embolism (1 study) and recurrent ischemic stroke (1).
Stroke or systemic embolism
downin humans1RR 0.74
1 study
Stroke or systemic embolism
downin humans1RR 0.74
Asundexian lowers the risk of stroke or systemic embolism in humans (cardiovascular disease; sensitivity analysis excluding an influential trial) (RR 0.74, 95% CI 0.65–0.84).
“Sensitivity analyses excluding an influential trial reduced heterogeneity substantially and demonstrated a lower risk of stroke or systemic embolism (RR 0.74, 95% CI 0.65–0.84).”
Reviewcardiovascular disease; sensitivity analysis excluding an influential trial
Efficacy and Safety of Asundexian in Cardiovascular Diseases, Systemic Review and Meta-Analysis
AHA Scientific Sessions 2026 abstract
Recurrent ischemic stroke
downin humans1
1 study
Recurrent ischemic stroke
downin humans1
Asundexian lowers the risk of recurrent ischemic stroke in humans (recurrence prevention after stroke) (NNT ~ 53/year).
“asundexian significantly reduced recurrent ischemic strokes in the manufacturer-funded OCEANIC-STROKE phase III trial (NNT ~ 53/year) without an increased bleeding risk.”
Reviewrecurrence prevention after stroke
Frailty, formulas, and subtle effects – (Late) evidence quickies, calendar week 16
EvidenzUpdate
Who is developing asundexian?
1 company: Bayer.
- Companies
- BayerPhase 3prevention of stroke or systemic embolism, atrial fibrillation
Trial sponsors
Company1 trialPhase 314,830 people